CL2013002436A1 - Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis. - Google Patents

Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis.

Info

Publication number
CL2013002436A1
CL2013002436A1 CL2013002436A CL2013002436A CL2013002436A1 CL 2013002436 A1 CL2013002436 A1 CL 2013002436A1 CL 2013002436 A CL2013002436 A CL 2013002436A CL 2013002436 A CL2013002436 A CL 2013002436A CL 2013002436 A1 CL2013002436 A1 CL 2013002436A1
Authority
CL
Chile
Prior art keywords
disease
crystalline form
oxipirazin
osteoporosis
tetrahydro
Prior art date
Application number
CL2013002436A
Other languages
English (en)
Inventor
Robert M Jones
Anthony C Blackburn
Sangdon Han
Biman B Pal
Jaimie Karyn Reuter
Antonio Garrido Montalban
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of CL2013002436A1 publication Critical patent/CL2013002436A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMAS CRISTALINAS DE LA ((S)-1 -HIDROXIMETIL-2,2-DIMETILPROPIL)AMIDA DEL ÁCIDO (1 AS,5AS)-2-(4-OXIPIRAZIN-2-II)-1 A,2,5,5A-TETRAHIDRO-1 H-2,3-DIAZACICLOPROPA[A]PENTALENO-4-CARBOXILICO COMPUESTO 1) Y A SUS COMPOSICIONES FARMACÉUTICAS QUE MODULAN LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE C13 2 Y, POR CONSIGUIENTE, SON ÚTILES EN EL TRATAMIENTO DE TRASTORNOS MEDIADOS POR EL RECEPTOR C13 2 , COMO, OSTEOARTRITIS; DOLOR; HIPERALGESIA; ALODINIA; HIPERALGESIA INFLAMATORIA; HIPERALGESIA NEUROPÁTICA; NOCICEPCIÓN AGUDA; OSTEOPOROSIS; ESPASTICIDAD ASOCIADA CON LA ESCLEROSIS MÚLTIPLE; TRASTORNOS AUTOINMUNITARIOS; REACCIONES ALÉRGICAS; INFLAMACIÓN DEL SNC, POR EJEMPLO; ATEROSCLEROSIS; ACTIVIDAD DE LAS CÉLULAS INMUNITARIAS E INFLAMACIÓN INDESEADAS ASOCIADAS CON UN TRASTORNO SELECCIONADO ENTRE: OSTEOARTRITIS, ANAFILAXIA, ENFERMEDAD DE BEHCET, RECHAZO DE INJERTO, VASCULITIS, GOTA, ESPONDILITIS, ENFERMEDAD VÍRICA, ENFERMEDAD BACTERIANA, LUPUS, ENFERMEDAD INFLAMATORIA INTESTINAL, HEPATITIS AUTOINMUNITARIA Y DIABETES MELLITUS DE TIPO 1; DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD; TOS; LEUCEMIA; LINFOMA; TUMORES DEL SNC; CÁNCER DE PRÓSTATA; ENFERMEDAD DE ALZHEIMER; LESIÓN PROVOCADA POR UN ACCIDENTE CEREBROVASCULAR; DEMENCIA; ESCLEROSIS LATERAL AMIOTRÓFICA Y ENFERMEDAD DE PARKINSON. PROCESO DE PREPARACIÓN DE UNA FORMA CRISTALINA ANHIDRA DEL COMPUESTO DE FÓRMULA (1).        
CL2013002436A 2011-02-25 2013-08-23 Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis. CL2013002436A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02

Publications (1)

Publication Number Publication Date
CL2013002436A1 true CL2013002436A1 (es) 2014-01-24

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002436A CL2013002436A1 (es) 2011-02-25 2013-08-23 Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis.

Country Status (19)

Country Link
US (4) US9458136B2 (es)
EP (3) EP3395812B8 (es)
JP (1) JP5945554B2 (es)
KR (1) KR102036932B1 (es)
CN (1) CN103608343B (es)
AU (1) AU2012222146B2 (es)
BR (1) BR112013021549B1 (es)
CA (1) CA2827057C (es)
CL (1) CL2013002436A1 (es)
CO (1) CO6852066A2 (es)
DK (1) DK3395812T3 (es)
EA (1) EA035989B1 (es)
ES (1) ES2932441T3 (es)
IL (1) IL227782A (es)
MX (1) MX346533B (es)
MY (1) MY165767A (es)
SG (1) SG192817A1 (es)
WO (1) WO2012116276A1 (es)
ZA (1) ZA201306402B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201901293RA (en) 2009-08-28 2019-03-28 Arena Pharm Inc Cannabinoid receptor modulators
KR102036932B1 (ko) * 2011-02-25 2019-10-25 아레나 파마슈티칼스, 인크. 축합 아자사이클 (칸나비노이드 수용체 조절제)의 결정질 형태 및 제조 방법
MX346644B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
US20190160058A1 (en) * 2016-04-10 2019-05-30 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
MX2019013311A (es) * 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2023059610A1 (en) 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
JP2005516004A (ja) 2001-12-07 2005-06-02 ヴァージニア コモンウェルス ユニバーシティ 新形成の治療
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
AU2005278781B2 (en) 2004-07-12 2009-06-18 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体，含有该配体的药物组合物及其制备方法
WO2006129178A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
KR20090024789A (ko) 2006-07-04 2009-03-09 얀센 파마슈티카 엔.브이. 치환 복소환기를 갖는 벤즈이미다졸 카나비노이드 작용제
CN101516839A (zh) 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
US8193369B2 (en) 2007-03-30 2012-06-05 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
ES2439255T3 (es) 2007-06-21 2014-01-22 Cara Therapeutics, Inc. Imidazoheterociclos sustituidos
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20120004222A1 (en) 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
SG10201901293RA (en) * 2009-08-28 2019-03-28 Arena Pharm Inc Cannabinoid receptor modulators
KR102036932B1 (ko) * 2011-02-25 2019-10-25 아레나 파마슈티칼스, 인크. 축합 아자사이클 (칸나비노이드 수용체 조절제)의 결정질 형태 및 제조 방법
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX346644B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Also Published As

Publication number Publication date
EP3395812B1 (en) 2022-09-28
EP3395812B8 (en) 2022-11-02
AU2012222146B2 (en) 2017-05-11
CA2827057C (en) 2022-06-07
MY165767A (en) 2018-04-23
US20190308952A1 (en) 2019-10-10
BR112013021549B1 (pt) 2022-01-11
EA035989B1 (ru) 2020-09-09
JP5945554B2 (ja) 2016-07-05
CO6852066A2 (es) 2014-01-30
EA201391233A1 (ru) 2014-02-28
EP4166552A1 (en) 2023-04-19
DK3395812T3 (da) 2022-11-28
NZ614787A (en) 2014-08-29
US9458136B2 (en) 2016-10-04
MX2013009760A (es) 2014-06-11
AU2012222146A1 (en) 2013-09-19
US10183930B2 (en) 2019-01-22
ES2932441T3 (es) 2023-01-19
US10981895B2 (en) 2021-04-20
IL227782A0 (en) 2013-09-30
IL227782A (en) 2017-02-28
CA2827057A1 (en) 2012-08-30
KR102036932B1 (ko) 2019-10-25
US20170144993A1 (en) 2017-05-25
US11560369B2 (en) 2023-01-24
MX346533B (es) 2017-03-14
KR20140025353A (ko) 2014-03-04
BR112013021549A2 (pt) 2016-11-01
US20140135345A1 (en) 2014-05-15
EP2678330A1 (en) 2014-01-01
US20210380560A1 (en) 2021-12-09
SG192817A1 (en) 2013-09-30
CN103608343A (zh) 2014-02-26
JP2014506602A (ja) 2014-03-17
EP3395812A1 (en) 2018-10-31
WO2012116276A1 (en) 2012-08-30
CN103608343B (zh) 2019-02-01
ZA201306402B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CL2013002436A1 (es) Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis.
CL2016003247A1 (es) Composiciones y métodos para la expresión de arns guía usando el promotor h1
EP4023641A3 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
EP4071161A4 (en) PROCESS FOR SYNTHESIS OF URSODEOXYCHOLIC ACID USING BA AS RAW MATERIAL
MY159252A (en) Process for the preparation of dopo-derived compounds and compositions thereof
MX2009010361A (es) Anticuerpos il-12 anti-humanos cristalinos.
MX2013013144A (es) Metodo para la produccion de un dimero mdi.
CL2012001461A1 (es) Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras.
MX2018014128A (es) 6.7.beta-epoxidos esteroideos como intermedios quimicos.
RU2014143726A (ru) Новый органический вулканизирующий агент на основе карданола, способ его получения и содержащая его каучуковая композиция для шин
IN2014DN02166A (es)
JP6705461B2 (ja) イソシアネート化合物の製造方法
MY169924A (en) Clear hydrophobic tpu
MX354648B (es) Materiales zeoliticos y metodos para su preparacion utilizando compuestos alqueniltrialquilamonio.
IN2014MN02314A (es)
CN107001244B (zh) 异氰酸酯化合物的制造方法
BR112015010455A2 (pt) método para produção, isolamento e purificação de anti-triptase humana recombinante (osraat) a partir de sementes de arroz
MY160912A (en) Formulations
PH12016500749B1 (en) A method for preparing an intermediate of iopromide
CY1118348T1 (el) Μεθοδος παρασκευης μεταξαλονης
RU2013138900A (ru) Способ кормления гусят-бройлеров
WO2019003767A1 (ja) アルコキシアルキル基を有するイソシアヌル酸誘導体及びその製造方法
Kovaliskaia et al. (-)-Sclareol conversion in the Ritter’s reaction conditions
NZ594217A (en) Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
WO2015075693A8 (en) Process for the synthesis of (11 beta,17alpha)-17-acetoxy-11 -methyl-19-norpregn-4-en-3,20-dione